Safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population

Journal of Infectious Diseases

Volumn 209, Issue 1, 2014, Pages 12-23

  Van Der Velden, Maikel V W ^a   Fritz, Richard ^a   Pöllabauer, Eva Maria ^a   Portsmouth, Daniel ^a   Howard, M Keith ^a   Kreil, Thomas R ^a   Dvorak, Thomas ^a   Fritsch, Sandor ^a   Vesikari, Timo ^b   Diez Domingo, Javier ^c   Richmond, Peter ^d,e,f   Lee, Bee Wah ^g   Kistner, Otfried ^a   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a   Aichinger, Gerald ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c Centro Superior de Investigacion en Salud Publica   (Spain)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^g MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

cell culture; children; HA; heterosubtypic immunity; immunological priming; NA; neuraminidase; pediatric; Vero; whole virus H5N1 vaccine

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CHILL; CONTROLLED STUDY; CRYING; DECREASED APPETITE; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERHIDROSIS; IMMUNOGENICITY; INFANT; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALAISE; MALE; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; VACCINATION REACTION; VERO CELL; VIRUS NEUTRALIZATION; VIRUS STRAIN; VOMITING;

CELL CULTURE; CHILDREN; HA; HETEROSUBTYPIC IMMUNITY; IMMUNOLOGICAL PRIMING; NA; NEURAMINIDASE; PEDIATRIC; VERO; WHOLE-VIRUS H5N1 VACCINE;

ADOLESCENT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; VERO CELLS;

EID: 84891361903     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit498     Document Type: Article

References (45)

1. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Geneva, Switzerland: WHO, 2012. http://www.who.int/influenza/ human-animal-interface/H5N1-cumulative-table-archives/en/index.html. Accessed 1 October 2013.
2. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336:1534-41.
3. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420-8.
4. Watanabe Y, Ibrahim MS, Ellakany HF, et al. Acquisition of humantype receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog 2011; 7: e1002068.
5. Ambrose CS, Wu X. Evidence of homosubtypic but not heterosubtypic immunity in young children following wild-type influenza illness. Pediatr Infect Dis J 2011; 30:900-1.
6. Lynch GW, Selleck P, Sullivan JS. Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. J Mol Genet Med 2009; 3:205-9.
7. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respi Viruses 2013; 7:872-6.
8. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012; 55:26-32.
9. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005; 23:1284-93.
10. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. Geneva, Switzerland: WHO, 2011. http://www.who.int/influenza/ gisrs
11. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
12. Couch RB, Atmar RL, Franco LM, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013; 207:974-81.
13. Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines 2011; 10:1683-95.
14. Rockman S, Brown LE, Barr IG, et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza Vaccine. J Virol 2013; 87:3053-61.
15. Ehrlich HJ, Müller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84.
16. Barrett PN, Portsmouth D, Ehrlich HJ. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Rev Vaccines 2013; 12:395-413.
17. van der Velden MVW, Aichinger G, Pollabauer EM, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012; 30:6127-35.
18. Fritz R, Sabarth N, Kiermayr S, et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012; 205:28-34.
19. Committee for Human Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. Report no. CPMP/VEG/4717/03 EMEA/CPMP/VEG/4717/2003-Rev.1. London: European Medicines Agency, 2008. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003869.pdf. Accessed 1 October 2013.
20. Committee for Human Medicinal Products. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Report no. EMEA/CHMP/VWP/263499/2006. London: European Medicines Agency, 2007. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003872.pdf. Accessed 1 October 2013.
21. Committee for Proprietary Medicinal Products. Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure. Report no. EMEA/CPMP/VEG/4986/03. London: European Medicines Agency, 2004. http://www. emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003815.pdf. Accessed 1 October 2013.
22. Kistner O, Howard MK, Spruth M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36.
23. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: FDA, 2011. http://www.fda.gov/downloads/BiologicsBlood Vaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vac cines/ucm091977.pdf. Accessed 1 October 2013.
24. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
25. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. BullWorld Health Organ 1975; 52:43-50.
26. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. Report no. CPMP/BWP/214/96. London: European Agency for the Evaluation of Medicinal Products, 1997. http://www.emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003945.pdf. Accessed 1 October 2013.
27. Howard MK, Sabarth N, Savidis-Dacho H, et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011; 6:e23791.
28. Vepacel influenza vaccine (whole virion, inactivated): EPAR summary for the public. London: European Medicines Agency, 2012. http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/ 002089/WC500124226.pdf. Accessed 1 October 2013.
29. Pandemic influenza vaccine H5N1 Baxter AG: EPAR summary for the public. London: European Medicines Agency, 2012. http://www.ema. europa.eu/docs/en-GB/ document-library/EPAR-Summary-for-the-public/human/001200/WC500049617.pdf. Accessed 1 October 2013.
30. Agresti A, Coull BA. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 1996; 52:1103-11.
31. Diez-Domingo J, Garces-Sanchez M, Baldo JM, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-e46.
32. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:e762-e770.
33. Vesikari T, Forsten A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R. Homologous and heterologous antibody responses to a one-year booster dose of an MF59® adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 2012; 8: 921-8.
34. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, agestratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101.
35. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.
36. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982; 69:404-8.
37. Boyer KM, Cherry JD, Wright PF, et al. Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines. J Infect Dis 1977; 136(Suppl):S579-83.
38. Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977; 136:623-32.
39. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Pepin S, Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One 2008; 3:e4028.
40. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91.
41. Wu J, Liu SZ, Dong SS, et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 2010; 28:6221-7.
42. Pica N, Hai R, Krammer F, et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 2012; 109: 2573-8.
43. Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012; 109:9047-52.
44. Qiu C, Huang Y, Wang Q, et al. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin Infect Dis 2012; 54:17-24.
45. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208: 181-93.